Switching from Ozempic to Rybelsus: A Guide to Your Transition

Why Patients Use Semaglutide
Patients use semaglutide, available as Ozempic and Rybelsus, primarily for managing type 2 diabetes and, in some cases, for weight loss. Semaglutide works by mimicking the action of a natural hormone that regulates blood sugar levels, slows digestion, and reduces appetite, leading to better control of blood glucose and supporting weight management. It is particularly favored for its ability to improve blood sugar levels while also offering cardiovascular benefits, such as reducing the risk of major adverse cardiovascular events in patients with type 2 diabetes.

Reasons to Switch from Ozempic to Rybelsus
Some patients may wish to switch from injectable Ozempic to oral Rybelsus for various reasons. A primary motivation is the convenience and comfort of taking a pill rather than dealing with regular injections, which can be daunting for those with needle anxiety or those who find injections disruptive to their daily routines. Additionally, switching to an oral medication can simplify medication management, improve adherence, and fit more seamlessly into a patient’s lifestyle, especially for those who travel frequently or prefer not to carry injection supplies.

Switching Schedule
For patients currently taking 0.5 mg of semaglutide weekly via subcutaneous injection (Ozempic), the recommended transition involves starting Rybelsus at either 7 mg or 14 mg orally up to 7 days after the last injection. This allows for a smooth transition without gaps in medication. However, it is important to note that there is no directly equivalent oral dose for patients taking the 1 mg subcutaneous dose of Ozempic, and they should consult their healthcare provider for personalized advice on adjusting their medication regimen during the switch.

Reference: Medscape